A biotechnology company focused on developing precision therapies for cancer and autoimmune diseases using proprietary technology platforms.

Hummingbird Bioscience

Hummingbird Bioscience is a data-driven precision biotherapeutics team discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology, and wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. At Hummingbird Bioscience, our commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. 

Sign up for our updates here: https://bit.ly/HMBDNews

Heritas Capital

Amgen Ventures

Mirae Asset Venture Investment

Pureos Bioventures

Seeds Capital

Novo Holdings

Octagon Capital Advisors

Polaris Partners

Droia Ventures

EDBI

Frazier Healthcare Partners

Kon Yew Kwek, BMBCh, DPhil, Senior Vice President of Clinical Development at Hummingbird Bioscience will share our clinical development strategy and progress at the SCRI Clinical Trials Symposium 2024 (30-31 July): https://bit.ly/3xIprzF 

Kon Yew will also participate in a panel discussing the possibilities for biotechs conducting clinical trials in Singapore. 

 31 July 2024 (Day 2)
 Time: 11 am – 12.30 pm 
 
 Organized by the Singapore Clinical Research Institute (SCRI), the two-day event aims to showcase the impact of and opportunities for clinical trials in Singapore. 
 
 #clinicaldevelopment #clinicaltrials #singapore

Hummingbird Bioscience partnered with the Children's Wishing Well to spark children’s interest in biology and conservation. In a visit to Science Centre Singapore last month, volunteers from our team accompanied ~40 children on the “Young Geneticist Trail”, for the children to learn about DNA and genetic inheritance. The children also viewed a screening of the “Jane Goodall – Reasons for Hope” documentary at the Omni-theatre. We hope the children enjoyed their day! 

#csr #scienceeducation #biology

Gary Khoo 邱思贤, VP of CMC at Hummingbird Bioscience will speak at a panel at World ADC Asia (25-27 June, Incheon, South Korea). Gary will share about how we manage our ADC production processes. The panel will discuss supply chain management of ADC components in Asia Pacific, and navigation of European and American markets. If you will be at World ADC Asia, connect with Gary at the panel discussion. 

#worldADC #ADC World ADC Event Series

Hummingbird Bioscience will present its next-generation antibody-drug conjugate capabilities (ADC) at PEGS Boston 2024 (13-17 May). 
 
For the first time, the company will present how its proprietary 4th generation ADC platform overcomes the resistance observed with earlier generation single payload ADCs. The company will also present how its proprietary Rational Antibody Discovery (RAD) platform enables epitope-directed discovery against challenging targets for optimal drug properties. 
 
Read more on the press release: https://bit.ly/3UGUYd0

This is the third year that Hummingbird Bioscience has collaborated with South West Community Development Council and People's Association to give back to the community. On 23rd and 24th February 2024, our CSR committee and volunteers packed and distributed bags of food and necessities to households in Telok Blangah. We hope that our contributions have made a positive impact on the community. 
 
The initiative is part of a larger program (Adopt @ South West) by the South West CDC, to provide well-rounded assistance in the areas of social support & wellness, education & enrichment, and home maintenance & improvement.

The Hummingbird Bioscience team will present our clinical development, CMC, and regulatory capabilities at Clinical Trials Festival Asia and Biologics Manufacturing Asia, at Marina Bay Sands Expo & Convention Centre in Singapore on 20-21 March. 
 
Carlo Polo, Senior Director of Regulatory Science, and Kon Yew Kwek, Senior Vice President of Clinical Development will present regulatory insights on Asia’s clinical trials and our approach to precision oncology. 
 
Gary Khoo, Vice President of CMC, will present the key considerations in developing and manufacturing next generation ADCs. Gary will also be on a panel discussing the Asia biomanufacturing market. 
 
IMAPAC #clinicaldevelopment #regulatoryscience #ADC

Domain Not Resolving

CrUX Dataset

CloudFront

CrUX Top 10m

SiteGround CAPTCHA

Chief Medical Officer

Eric Rowinsky

Chief Technology Officer

Konrad Paszkiewicz

Chief Development Officer

Leah DiMascio

Associate Director

Ben Ayers

Associate Director, Project Management

Erica Osbourne, PMP

Legal

Jovina Low

Operations

Michelle Su

Quality

Jennifer Yeo

Healthcare

Luis Garcia

Sasha Davani

Daniel Estes

Kiel Kim

Kenneth Harrison

Piers Ingram

CEO & Co-Founder

Josh House

Chief Financial Officer

Guy Heathers

Vice President Business Development

Angele Maki

Chief Business Officer

Jerome Boyd-Kirkup

CSO & Co-Founder

Oncology Companies

Biotechnology Late Stage Companies With Less Than $50M in Revenue

Therapeutics Companies With More Than $1M in Revenue (Top 10K)

Association of Southeast Asian Nations (ASEAN) Late Stage Companies

Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

Series C - Hummingbird Bioscience

SK Holdings

Series B - Hummingbird Bioscience

Decheng Capital

Series A - Hummingbird Bioscience

Woodlands

North Region

Singapore

Asia

8 biotech companies advancing new treatments for breast cancer in 2024

Hummingbird Bioscience Announces Key Leadership Appointments

Hummingbird Bioscience Archives - GEN

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate ...

Hummingbird's dual ADC payloads deliver one-two punch to tumors

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024

news impact assignment basic	general	Jul 11, 2024 2:23 PM	2daed3e1
public peers	general	Jul 11, 2024 2:23 PM	8e684728
news daily refresh	general	Jul 11, 2024 2:23 PM	ceb31e3f
news processing daily refresh	general	Jul 11, 2024 2:23 PM	8ed07552
news impact assignment daily	general	Jul 11, 2024 2:23 PM	75b22854
news processing basic	general	Jul 11, 2024 2:23 PM	d7d93d52
company summary	general	Jul 11, 2024 11:04 PM	6cf44727
signals	general	Jul 11, 2024 2:23 PM	fcaebaf7
crunchbase trigger	general	Nov 25, 2024 9:09 AM	ac681aef
crunchbase profile	general	Nov 25, 2024 11:35 AM	cd0d64a6
li profile	general	Jul 11, 2024 2:23 PM	c655bd60
translate crunchbase fundingrounds	general	Nov 25, 2024 2:18 PM	638ebf75
peers	general	Jul 11, 2024 2:23 PM	6557b40e
news basic	general	Jul 11, 2024 2:23 PM	6db4a45f
bundesanzeiger	filings	Jul 11, 2024 2:23 PM	ab130d47
financials download nd	financials
private financials	financials

HUMM

COM:HUMMINGBIRDBIOSCIENCE

Hummingbird Bioscience